MERGE
30.4.2024 10:01:35 CEST | Business Wire | Press release
Merge, which provides unified APIs for B2B SaaS organizations to easily add hundreds of integrations to their products, has officially expanded to Europe with the establishment of its Berlin-based team. The expansion reinforces Merge’s commitment to serving European customers’ integration wants and needs effectively.
Data protection has been a top priority for European organizations since The General Data Protection Regulation (GDPR) took effect in 2018. As a result, Merge remains steadfast in prioritizing investments in security, product infrastructure, and support to assist European companies with their product integration needs.
To ensure the highest standards of security and compliance, Merge maintains ISO 27001 and SOC 2 Type 2 certifications. Additionally, Merge puts in place Data Processing Agreements (DPAs) with all customers, committing to processing data transfers in accordance with GDPR’s Standard Contractual Clauses. Furthermore, Merge supports both multi-tenant and single-tenant environments, enabling customers to fully control where their end-user data is stored.
“We know how important it is for our European customers to securely and quickly offer customer-facing integrations, which is why we’ve prioritized building and enhancing our infrastructure, security-focused features, and Europe-based software integrations,” said Shensi Ding, co-founder and CEO of Merge. “With our new team based in Berlin, we have even faster, dedicated support, providing our customers everything they need to securely and confidently use Merge.”
Merge is proud to be trusted by hundreds of Europe-based companies, including Eloomi, Payhawk, Staffbase, Hofy, TravelPerk, Ledgy, and Causal. Today, 30% of Merge’s customers are based in Europe, and these investments are aimed at better serving this market. Currently offering 200+ global integrations, Merge is focused on adding European providers as it continues to scale.
"Ledgy is being used by organizations in 45+ countries, and Merge has helped us along the way,” said Armon Bättig, head of sales at Zürich-based Ledgy - an equity management platform that uses Merge to power its HRIS integrations.
To learn more about Merge’s integrations for GDPR-compliant companies, visit: www.merge.dev/eu
European companies can visit the Merge booth at Pendomonium’s Mind the Product in London on June 20th, Berlin on June 27th, and at SaaStock in Dublin on October 14th.
About Merge:
Merge is a product integration platform that offers a suite of unified APIs to empower B2B SaaS organizations to seamlessly add hundreds of integrations to their apps. Merge’s platform makes secure data access easy by offering unified APIs across key software categories, including HRIS, accounting, CRM, file storage, and more. By handling the full integration lifecycle, Merge empowers companies to close deals faster, reduce customer churn, and save engineering costs.
Merge is backed by Accel Partners, New Enterprise Associates (NEA), and Addition, and has received $75 million in funding. Merge was founded in 2020 by Shensi Ding and Gil Feig and has offices in San Francisco, New York City and Berlin. For more information, visit Merge's website and follow the company on LinkedIn and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430162409/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom